GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+21.17%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$339M
AUM Growth
+$339M
(-9.4%)
Cap. Flow
-$75.1M
Cap. Flow
% of AUM
-22.18%
Top 10 Holdings %
Top 10 Hldgs %
54.05%
Holding
69
New
17
Increased
9
Reduced
11
Closed
24
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$20.7M |
| 2 |
BLUE
bluebird bio
BLUE
|
$16.5M |
| 3 |
PTC Therapeutics
PTCT
|
$16M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$11.7M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$10.9M |
Top Sells
| 1 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
$23.5M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$16.7M |
| 3 |
Viatris
VTRS
|
$14.4M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$14.2M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$14.2M |
Sector Composition
| 1 | Healthcare | 84.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $29.6M | 8.71% | 1,250,000 -600,000 | -32% | -$14.2M |
|
|
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $24.7M | 7.25% | 500,000 +237,500 | +90% | +$11.7M |
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $23.1M | 6.81% | 175,000 -60,000 | -26% | -$7.93M |
|
|
4
PTC Therapeutics
PTCT
$3.92B
| $22.8M | 6.7% | 675,000 +475,000 | +238% | +$16M |
|
|
5
Alnylam Pharmaceuticals
ALNY
$58.5B
| $20.7M | 6.09% | +210,000 | New | +$20.7M |
|
|
BLUE
6
DELISTED
bluebird bio
BLUE
| $16.5M | 4.85% | +105,000 | New | +$16.5M |
|
7
argenx
ARGX
$43.6B
| $12.4M | 3.66% | 150,000 | – | – |
|
8
Ascendis Pharma
ASND
$11.8B
| $11.6M | 3.43% | 175,000 +35,000 | +25% | +$2.33M |
|
|
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $10.9M | 3.22% | +242,000 | New | +$10.9M |
|
10
Mersana Therapeutics
MRSN
$36.5M
| $10.7M | 3.15% | 600,000 +321,756 | +116% | +$5.75M |
|
11
Arrowhead Research
ARWR
$3.05B
| $9.52M | 2.8% | 700,000 -100,000 | -13% | -$1.36M |
|
12
Assembly Biosciences
ASMB
$190M
| $9.21M | 2.71% | 235,000 +85,000 | +57% | +$3.33M |
|
13
Exelixis
EXEL
$10.1B
| $8.61M | 2.53% | +400,000 | New | +$8.61M |
|
14
Acadia Pharmaceuticals
ACAD
$4.38B
| $8.17M | 2.4% | 535,000 +135,000 | +34% | +$2.06M |
|
|
DRNA
15
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.09M | 2.38% | 660,000 -290,000 | -31% | -$3.55M |
|
|
ADMS
16
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $7.62M | 2.24% | 295,000 -30,000 | -9% | -$775K |
|
|
KDMN
17
DELISTED
Kadmon Holdings, Inc.
KDMN
| $7.58M | 2.23% | 1,900,000 +300,000 | +19% | +$1.2M |
|
|
ECYT
18
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $6.9M | 2.03% | 500,000 -1,700,000 | -77% | -$23.5M |
|
19
Rocket Pharmaceuticals
RCKT
$354M
| $6.87M | 2.02% | 350,000 -500,000 | -59% | -$9.82M |
|
20
Madrigal Pharmaceuticals
MDGL
$9.76B
| $6.57M | 1.93% | +23,500 | New | +$6.57M |
|
|
TECX
21
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $6.57M | 1.93% | +230,000 | New | +$6.57M |
|
|
CBIO
22
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $6.45M | 1.9% | 400,000 +150,000 | +60% | +$2.42M |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $6.23M | 1.83% | 900,000 | – | – |
|
|
OBSV
24
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $6.06M | 1.78% | 400,000 | – | – |
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| $5.56M | 1.64% | +186,019 | New | +$5.56M |
|